Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Ryanodine calcium channel: a novel channelopathy for seizures.

Nagrani T, Siyamwala M, Vahid G, Bekheit S.

Neurologist. 2011 Mar;17(2):91-4. doi: 10.1097/NRL.0b013e3181ef0d52.

PMID:
21364362
2.

Deadly proposal: a case of catecholaminergic polymorphic ventricular tachycardia.

Heiner JD, Bullard-Berent JH, Inbar S.

Pediatr Emerg Care. 2011 Nov;27(11):1065-8. doi: 10.1097/PEC.0b013e3182360606.

PMID:
22068070
3.

Search for cardiac calcium cycling gene mutations in familial ventricular arrhythmias resembling catecholaminergic polymorphic ventricular tachycardia.

Marjamaa A, Laitinen-Forsblom P, Lahtinen AM, Viitasalo M, Toivonen L, Kontula K, Swan H.

BMC Med Genet. 2009 Feb 12;10:12. doi: 10.1186/1471-2350-10-12.

4.

Calcium leak through ryanodine receptors leads to atrial fibrillation in 3 mouse models of catecholaminergic polymorphic ventricular tachycardia.

Shan J, Xie W, Betzenhauser M, Reiken S, Chen BX, Wronska A, Marks AR.

Circ Res. 2012 Aug 31;111(6):708-17. doi: 10.1161/CIRCRESAHA.112.273342. Epub 2012 Jul 24.

5.

Arrhythmogenic channelopathy syndromes presenting as refractory epilepsy.

Hazle MA, Shellhaas RA, Bradley DJ, Dick M 2nd, Lapage MJ.

Pediatr Neurol. 2013 Aug;49(2):134-7. doi: 10.1016/j.pediatrneurol.2013.03.017.

PMID:
23859862
6.

Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives.

van der Werf C, Nederend I, Hofman N, van Geloven N, Ebink C, Frohn-Mulder IM, Alings AM, Bosker HA, Bracke FA, van den Heuvel F, Waalewijn RA, Bikker H, van Tintelen JP, Bhuiyan ZA, van den Berg MP, Wilde AA.

Circ Arrhythm Electrophysiol. 2012 Aug 1;5(4):748-56. doi: 10.1161/CIRCEP.112.970517. Epub 2012 Jul 10.

7.

Characterization of a novel mutation in the cardiac ryanodine receptor that results in catecholaminergic polymorphic ventricular tachycardia.

Jiang D, Jones PP, Davis DR, Gow R, Green MS, Birnie DH, Chen SR, Gollob MH.

Channels (Austin). 2010 Jul-Aug;4(4):302-10. Epub 2010 Jul 14.

8.

Catecholaminergic polymorphic ventricular tachycardia: recent mechanistic insights.

Kontula K, Laitinen PJ, Lehtonen A, Toivonen L, Viitasalo M, Swan H.

Cardiovasc Res. 2005 Aug 15;67(3):379-87. Review.

PMID:
15913575
9.

A novel mutation in FKBP12.6 binding region of the human cardiac ryanodine receptor gene (R2401H) in a Japanese patient with catecholaminergic polymorphic ventricular tachycardia.

Aizawa Y, Ueda K, Komura S, Washizuka T, Chinushi M, Inagaki N, Matsumoto Y, Hayashi T, Takahashi M, Nakano N, Yasunami M, Kimura A, Hiraoka M, Aizawa Y.

Int J Cardiol. 2005 Mar 18;99(2):343-5.

PMID:
15749201
10.

Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations.

Kujala K, Paavola J, Lahti A, Larsson K, Pekkanen-Mattila M, Viitasalo M, Lahtinen AM, Toivonen L, Kontula K, Swan H, Laine M, Silvennoinen O, Aalto-Setälä K.

PLoS One. 2012;7(9):e44660. doi: 10.1371/journal.pone.0044660. Epub 2012 Sep 4.

11.

Catecholaminergic polymorphic ventricular tachycardia.

Liu N, Colombi B, Raytcheva-Buono EV, Bloise R, Priori SG.

Herz. 2007 May;32(3):212-7. Review.

PMID:
17497254
12.

Involvement of the cardiac ryanodine receptor/calcium release channel in catecholaminergic polymorphic ventricular tachycardia.

Marks AR, Priori S, Memmi M, Kontula K, Laitinen PJ.

J Cell Physiol. 2002 Jan;190(1):1-6. Review.

PMID:
11807805
13.

Ryanodine receptor-targeted anti-arrhythmic therapy.

Wehrens XH, Lehnart SE, Marks AR.

Ann N Y Acad Sci. 2005 Jun;1047:366-75. Review.

PMID:
16093511
14.

Human cardiac ryanodine receptor mutations in ion channel disorders in Japan.

Aizawa Y, Mitsuma W, Ikrar T, Komura S, Hanawa H, Miyajima S, Miyoshi F, Kobayashi Y, Chinushi M, Kimura A, Hiraoka M, Aizawa Y.

Int J Cardiol. 2007 Mar 20;116(2):263-5. Epub 2006 Jul 14.

PMID:
16843546
15.

Distinct U wave changes in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT).

Aizawa Y, Komura S, Okada S, Chinushi M, Aizawa Y, Morita H, Ohe T.

Int Heart J. 2006 May;47(3):381-9.

16.

Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells.

Itzhaki I, Maizels L, Huber I, Gepstein A, Arbel G, Caspi O, Miller L, Belhassen B, Nof E, Glikson M, Gepstein L.

J Am Coll Cardiol. 2012 Sep 11;60(11):990-1000. doi: 10.1016/j.jacc.2012.02.066. Epub 2012 Jun 27.

17.

Ryanodine receptors and ventricular arrhythmias: emerging trends in mutations, mechanisms and therapies.

George CH, Jundi H, Thomas NL, Fry DL, Lai FA.

J Mol Cell Cardiol. 2007 Jan;42(1):34-50. Epub 2006 Nov 1. Review.

PMID:
17081562
18.

Molecular and electrophysiological bases of catecholaminergic polymorphic ventricular tachycardia.

Mohamed U, Napolitano C, Priori SG.

J Cardiovasc Electrophysiol. 2007 Jul;18(7):791-7. Review.

PMID:
17578347
19.
20.

High prevalence of exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia mutation-positive family members diagnosed by cascade genetic screening.

Haugaa KH, Leren IS, Berge KE, Bathen J, Loennechen JP, Anfinsen OG, Früh A, Edvardsen T, Kongsgård E, Leren TP, Amlie JP.

Europace. 2010 Mar;12(3):417-23. doi: 10.1093/europace/eup448. Epub 2010 Jan 26.

PMID:
20106799

Supplemental Content

Support Center